GlassScriptPhysician profile
Shiva Kheradmand
NPI 1457884298
$9,137.24
in general payments reported to CMS, 2019-2025
36 companies · $2,702 in 2025
The $2,702 reported for 2025 was more than what 83% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $559 · 2020: $35.27 · 2021: $415 · 2022: $1,138 · 2023: $2,120 · 2024: $2,168 · 2025: $2,702.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,738 · Education: $252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,738.15 |
| Education | $251.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,207.78 | 2020-2025 | |
| Genzyme Corporation | $1,141.41 | 2021-2025 | |
| Lilly USA, LLC | $992.64 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Incyte Corporation | $884.73 | 2022-2025 | Opzelura |
| Leo Pharma INC. | $778.49 | 2022-2025 | Adbry |
| Amgen INC. | $690.95 | 2022-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $402.29 | 2021-2025 | Dupixent, Libtayo |
| Pfizer INC. | $372.18 | 2022-2025 | |
| Janssen Biotech, INC. | $326.59 | 2023-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $306.81 | 2022-2025 | |
| Genentech USA, INC. | $291.08 | 2019-2024 | Xolair |
| E.R. Squibb & Sons, L.L.C. | $244.28 | 2023-2025 | Sotyktu |
| Dermavant Sciences, INC. | $237.51 | 2023-2024 | Vtama |
| Ucb, INC. | $199.27 | 2024-2025 | Bimzelx |
| Kyowa Kirin, INC. | $119.15 | 2019 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyne Pharmaceuticals INC. | $111.53 | 2021 | |
| Eli Lilly and Company | $99.00 | 2025 | |
| Chiesi USA, INC. | $87.66 | 2025 | Filsuvez |
| Sun Pharmaceutical Industries INC. | $75.64 | 2023-2025 | Absorica Ld, Winlevi |
| Galderma Laboratories, L.P. | $69.98 | 2022-2025 | Nemluvio |
| Arcutis Biotherapeutics, INC. | $60.44 | 2024-2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.33 | 2023-2025 | Spevigo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $53.77 | 2022 | |
| Organon LLC | $43.30 | 2025 | Vtama |
| Helsinn Therapeutics (U.S.), INC. | $41.09 | 2019 | |
| Csl Behring | $32.80 | 2024 | Haegarda |
| Fresenius Kabi USA, LLC | $31.68 | 2023 | |
| Krystal Biotech INC | $26.02 | 2023 | Vyjuvek |
| Botanix Sb INC | $25.13 | 2025 | Sofdra |
| Revance Therapeutics, INC. | $24.53 | 2024 | Daxxify |
| Verrica Pharmaceuticals INC. | $23.75 | 2025 | Ycanth |
| Almirall LLC | $20.01 | 2021 | |
| Epi Health, LLC | $17.11 | 2020 | |
| Mayne Pharma Commercial LLC | $15.35 | 2021 | |
| Cipher Pharmaceuticals US LLC | $14.79 | 2025 | Spinosad, Natroba |
| Solta Medical, A Division of Bausch Health US, LLC | $14.17 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shiva Kheradmand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.